TY  - JOUR
AU  - Magnano, Laura
AU  - Alonso-Alvarez, Sara
AU  - Alcoceba, Miguel
AU  - Rivas-Delgado, Alfredo
AU  - Muntañola, Anna
AU  - Nadeu, Ferran
AU  - Setoain, Xavier
AU  - Rodríguez, Sonia
AU  - Andrade-Campos, Marcio
AU  - Espinosa-Lara, Natalia
AU  - Rodríguez, Guillermo
AU  - Sancho, Juan Manuel
AU  - Moreno, Miriam
AU  - Mercadal, Santiago
AU  - Carro, Itziar
AU  - Salar, Antonio
AU  - Garcia-Pallarols, Francesc
AU  - Arranz, Reyes
AU  - Cannata, Jimena
AU  - Terol, María J
AU  - Teruel, Ana I
AU  - Jiménez-Ubieto, Ana
AU  - Rodriguez, Antonia
AU  - González de Villambrosía, Sonia
AU  - Bello, José L
AU  - López, Lourdes
AU  - Novelli, Silvana
AU  - de Cabo, Erik
AU  - Infante, María E
AU  - Pardal, Emilia
AU  - Monsalvo, Silvia
AU  - González, Marcos
AU  - Martín, Alejandro
AU  - Caballero, M Dolores
AU  - López-Guillermo, Armando
AU  - Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO)
PY  - 2019
DO  - 10.1111/bjh.15805
UR  - http://hdl.handle.net/10668/13606
T2  - British journal of haematology
AB  - The use of immunochemotherapy has improved the outcome of follicular lymphoma (FL). Recently, complete response at 30 months (CR30) has been suggested as a surrogate for progression-free survival. This study aimed to analyse the life expectancy of FL...
LA  - en
KW  - complete response
KW  - follicular lymphoma
KW  - survival
KW  - Aged
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Immunotherapy
KW  - Life Expectancy
KW  - Lymphoma, Follicular
KW  - Male
KW  - Middle Aged
KW  - Rituximab
KW  - Spain
KW  - Survival Rate
TI  - Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.
TY  - research article
VL  - 185
ER  -